Skip to main content

Table 1 Summary of Demographic Characteristics

From: Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy

 

6- and 7-Year Olds

8- to 12-Year Olds

 

ATX

PBO

 

ATX

PBO

 

Subject Characteristics

N = 184

N = 96

pa

N = 544

N = 316

pa

Gender, n (%)

      

   Female

54 (29.3)

22 (22.9)

.262

137 (25.2)

78 (24.7)

.935

   Male

130 (70.7)

74 (77.1)

 

407 (74.8)

238 (75.3)

 

Age (years), mean (SD)

7.2 (0.6)

7.1 (0.5)

. 273b

10.2 (1.4)

10.2 (1.4)

.606b

Origin, n (%)

      

   African descent

16 (8.7)

15 (15.6)

.179

81 (14.9)

40 (12.7)

.442

   Caucasian

137 (74.5)

64 (66.7)

 

374 (68.8)

234 (74.1)

 

   Hispanic

22 (12.0)

9 (9.4)

 

59 (10.8)

27 (8.5)

 

   Other

9 (4.9)

8 (8.3)

 

30 (5.5)

15 (4.7)

 

Prior stimulant treatment, n (%)

      

   No

133 (72.3)

68 (70.8)

.889

235 (43.3)

141 (44.6)

.722

   Yes

51 (27.7)

28 (29.2)

 

308 (56.7)

175 (55.4)

 

ADHD Subtype, n (%)

      

   Hyperactive/impulsive

10 (5.4)

2 (2.1)

.395

10 (1.8)

5 (1.6)

.828

   Inattentive

26 (14.1)

12 (12.5)

 

148 (27.2)

92 (29.1)

 

   Combined

148 (80.4)

82 (85.4)

 

386 (71.0)

219 (69.3)

 

ADHD Severity, mean (SD)

      

   Baseline ADHD Total T score

83.4 (9.5)

83.2 (8.7)

.862

81.7 (11.6)

81.2 (11.2)

.512

   Baseline CGI-ADHD-S score

5.0 (0.8)

5.0 (0.7)

.743

4.9 (0.8)

4.9 (0.8)

.909

  1. Abbreviations: ADHD = attention-deficit/hyperactivity disorder; ATX = atomoxetine; PBO = placebo; SD = standard deviation
  2. a p values were for comparing atomoxetine and placebo using a Fisher's exact test.
  3. b p values were for comparing atomoxetine and placebo using an ANOVA.